Romans 12:19
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$RLFTF #1 Most Read Board last hour
$RLFTF MisterPR from Stoktwts (opinion) SP will continue to rise and they can potentially uplist without RS in the future, imagine that. That is mind blowing. Get the word out about $RLFTF on all your social platforms this is not hype. / I've been thinking this all along IMO
$RLFTF Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19
RLFTF
+10.19%
BRPA
+36.41%
BRPAU
0.00%
Mon, March 29, 2021, 1:05 AM·10 min read
RLFTF
+10.19%
BRPA
+36.41%
BRPAU
0.00%
RADNOR, Pa., March 29, 2021 /PRNewswire/ -- NeuroRx, Inc. today reports 60-day results of the Phase 2b/3 trial of intravenously-administered ZYESAMI™ (aviptadil acetate) for the treatment of respiratory failure in critically-ill patients with COVID-19, which is being developed in collaboration with Relief Therapeutics Holding AG (SIX:RLF, OTCQB:RLFTF). Across all patients and sites, ZYESAMI™ met the primary endpoint for successful recovery from respiratory failure at days 28 (P = .014) and 60 (P = .013) and also demonstrated a meaningful benefit in survival (P = < .001) after controlling for ventilation status and treatment site.
(PRNewsfoto/NeuroRx)
In addition to the robust overall significance across all 196 treated patients at all 10 clinical sites, the prespecified analysis of recovery from respiratory failure is clinically and statistically significant in the 127 patients treated by High Flow Nasal Cannula (HFNC) (P = .02), compared to those treated with mechanical or non-invasive ventilation at tertiary care hospitals.
In this group, ZYESAMI™ patients had a 71% chance of successful recovery by day 28 vs. 48% in the placebo group (P = .017) and a 75% rate of successful recovery by day 60 vs. 55% in the placebo group (P = .036). Eighty-four percent (84%) of HFNC patients treated at tertiary medical centers with ZYESAMI™ survived to day 60 compared with 60% of those treated with placebo (P = .007).
(cont'd) https://finance.yahoo.com/news/neurorx-announces-zyesami-aviptadil-rlf-050500473.html
$RLFTF Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19
RLFTF
+10.19%
BRPA
+36.41%
BRPAU
0.00%
Mon, March 29, 2021, 1:05 AM·10 min read
RLFTF
+10.19%
BRPA
+36.41%
BRPAU
0.00%
RADNOR, Pa., March 29, 2021 /PRNewswire/ -- NeuroRx, Inc. today reports 60-day results of the Phase 2b/3 trial of intravenously-administered ZYESAMI™ (aviptadil acetate) for the treatment of respiratory failure in critically-ill patients with COVID-19, which is being developed in collaboration with Relief Therapeutics Holding AG (SIX:RLF, OTCQB:RLFTF). Across all patients and sites, ZYESAMI™ met the primary endpoint for successful recovery from respiratory failure at days 28 (P = .014) and 60 (P = .013) and also demonstrated a meaningful benefit in survival (P = < .001) after controlling for ventilation status and treatment site.
(PRNewsfoto/NeuroRx)
In addition to the robust overall significance across all 196 treated patients at all 10 clinical sites, the prespecified analysis of recovery from respiratory failure is clinically and statistically significant in the 127 patients treated by High Flow Nasal Cannula (HFNC) (P = .02), compared to those treated with mechanical or non-invasive ventilation at tertiary care hospitals.
In this group, ZYESAMI™ patients had a 71% chance of successful recovery by day 28 vs. 48% in the placebo group (P = .017) and a 75% rate of successful recovery by day 60 vs. 55% in the placebo group (P = .036). Eighty-four percent (84%) of HFNC patients treated at tertiary medical centers with ZYESAMI™ survived to day 60 compared with 60% of those treated with placebo (P = .007).
(cont'd) https://finance.yahoo.com/news/neurorx-announces-zyesami-aviptadil-rlf-050500473.html
ABSOLUTeLY !!!!
..it's a NeuroRX call.. ?? not a RLFTF business call.
$RLFTF #TheMath ..that's OK we're mentioned in this one..
GENEVA, Switzerland and RADNOR, Pa. , Sept. 21, 2020 /PRNewswire/ --
RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) Relief Therapeutics and NeuroRx, Inc. today announced the completion of their partnership agreement for the commercialization of RLF-100™(Aviptadil)
(Zyesami ) worldwide.
The two organizations have agreed to share all profits from sales of RLF-100 for all indications related to COVID-19 and potentially other respiratory indications on a global basis.
They have agreed that NeuroRx will lead commercialization in the United States , Canada , and Israel , while Relief will lead commercialization in Europe and the rest of the world.
Profits from sales will be allocated to Relief and NeuroRx on a 50/50 basis in the U.S., Canada and Israel , 85/15 (in favor of Relief) in Europe , and 80/20 (in favor of Relief) in all other territories.
Read More: https://www.prnewswire.com/news-releases/relief-and-neurorx-announce-partnership-for-global-commercialization-of-rlf-100-and-selection-of-commercial-partners-301134379.html
..I'm good w/the .014's I got.. I don't believe interested parties will let this ship go down.. way too much invested and so many other people and related Merida companies to come in and fill the gaps IMO .. feel like (not sure) Carlos got a going away care package already and we're gonna get to be new U.S, MX, EU gateway for a number of Merida companies.. but that's just a feeling..
HOW A CANNABIS DISPENSARY ECOMMERCE SITE CAN FAIL TO ATTRACT SALES https://420digitalstudio.com/how-a-cannabis-dispensary-ecommerce-site-can-fail-to-attract-sales/
$IGXT DD (opinion) by Tim on Ya-00: Our Partner Heritage Cannabis: Heritage achieves Strong Sales Growth, Reaches First Million Dollar Revenues Week.
Heritage Cannabis Announces Closing of Public Offering for Gross Proceeds of $13,846,000.
Heritage Cannabis Announces Receipt of the First Health Canada Cannabis Export License Granted for Brazil. IntelGenx is currently manufacturing CBD oral film strips for Heritage Cannabis that is scheduled to be delivered in Q221.
Heritage will no doubt be debuting our films in Canada, USA, Australia and now Brazil real soon.
Heritage has been building-out several successful brands with a diversified line of attractively packaged and obviously well-selling CBD cannabis products.
Also: Don't forget that Tilray Owns 100% Exclusive World Wide Rights to IntelGenx' Immediate Release Precision Dosed THC Oral Film Strips (USPTO Patent Pending).
Keep in mind, I posted last week Aleafia's recent press release stating that their first month of 2021 saw dramatically increased sales with revenues surpassing all of their previous 4th quarters numbers PRIMARELY driven by strong sales of their Kin Slips THC Oral Film Strips.
All cylinders will be firing real soon in my opinion. IGXT up +166% in the last 6 months tells me more than just Peter Theil has been paying attention to us.
Things I would like to see on Monday or Tuesday morning:
1. IntelGenx Announces First THC Oral Film Strip Order from Tilray
or,
2. IntelGenx Announces First Rizaport Migraine Oral Film Strip Order from Excelsis
or,
3. IntelGenx Announces VetaFilm Partnership with Merck Animal Health, Novartis Animal Health, etc, etc.
As we all witnessed with last weeks dramatic news of ATAI's proposed equity stake, the news cycle is "heating-up". One only needs to refer to the 3 month and 6 month charts for illustration of that fact.
Great luck to all next week!!
More and more Marijuana legalization will wake these Sleeping beauties up IMO ;)
$IGXT DD (opinion) by Tim on Ya-00
The company reported 3Q20 revenues of $510,000 an increase of +736% yoy results. Licensing and R&D generating impressive revenue increases. Next week IGXT will report similar yoy quarterly results of well over +800% increase in revenues. Next week Horst and Andre will delivery the very best and most positive company report in the company's history. Peter Theil's ATAI wants to take a US$12M equity stage in IGXT purchasing 59 million shares at .35 cents each representing a 25% stake in the company. When/if ATAI exercises all their warrants they will control 35% of the company and have directors placed on the board.
This ship has been most excellently "righted" and we are now about to embark on a life changing journey.
Share structure will look something like this after ATAI's purchase:
IGXT
171M total shares outstanding
78M shares held by insiders (47% insider ownership)
96M shares in the float
Major holders:
ATAI 59M shares
Horst and Ingrid Zerbe 10.3M shares
Will ATAI's stake in IGXT legitimize our companies equity to other hedge funds and Wall Street in general?
Of course.
Congrats to all shares holders old and new. 2021 is going to be a life changing and rewarding year for the faithful and the timely.
My opinion only~
Penny pincher trying to get big orders filled.. ;)
... link ?
...bigger and smarter crews will take notice.. ;)
CBD is one of the fastest-growing industry in the world. It is estimated to reach $1.8 billion by 2022 & forecasted to be a 23 billion dollar business by 2025.
$MSTO MasterBeat Corporations JTEC Automotive to Build 1968 Pro Touring Camaro in Collaboration with Blow by Racing March, 17 2021
https://marketwirenews.com/news-releases/masterbeat-corporations-jtec-automotive-to-build-196-6130997617309166.html
$MSTO MasterBeat Corporations JTEC Automotive to Build 1968 Pro Touring Camaro in Collaboration with Blow by Racing March, 17 2021
https://marketwirenews.com/news-releases/masterbeat-corporations-jtec-automotive-to-build-196-6130997617309166.html
$MSTO It's Gonna Get Good !!!
$GRLB is sitting in an Oven baking between Legal Canada and now Mexico.. ;) soon.. Shake 'n Bake !!!
$WLDF and a few others are sitting in an Oven baking between Legal Canada and now Mexico.. ;) soon.. ??
A 2 cent base now.. cool !!
$MSTO Just the beginning.. !!!
..that's good news.. though we're World wide interactive and lack of vaccinated people and variants will play a role they may not be accounting for..??
https://www.msn.com/en-us/health/medical/covid-19-pill-effective-in-preliminary-testing-may-be-holy-grail-of-pandemic-dr-marc-siegel-says/vi-BB1ekWM8?ocid=msedgdhp
$RLFTF DD by Wotan6 via Ya-h00: Never forget, the U.S. Department of Health and Human Services and the Department of Defense was REQUESTING Zyesami for the ISpy trials, not the other way around!
Motley pant w/out legs Ho's
..cool ;)
I copied that also I believe it was Vader on yaH00 there's a Vader69 here
w/the same post language:
https://investorshub.advfn.com/boards/profile.aspx?user=763840
..wish I was that sharp.. I'd know when to buy/sell ugh ;)
UknowIt!!!
$RLFTF Uncle Gee Gee DD from Ya-h00 (copy)
Top 10 Most Important Comments by Dr. Javitt in the recent Dr. Yo interview
*Put the dog distractions aside and LISTEN to what the man is saying!*
They are attempting to measure x-ray improvement in a placebo-controlled trial.
..yeah it's already a forgotten ticket.. I left the sale order in the pennies.. never know.. ;)
$RLFTF As noted in the NIH Director’s Blog earlier this month, “the quest to save more lives from COVID-19 isn’t even close to being finished, and researchers continue to work intensively to develop new and better treatments.” https://investorplace.com/2021/02/rlftf-why-little-known-relief-therapeutics-is-climbing-today-brpa-stock/
$MSTO MasterBeat Corporation's JTEC Automotive Profits from Sale of its 1969 Pontiac Firebird Custom Build 2-24-21
https://marketwirenews.com/news-releases/masterbeat-corporation-s-jtec-automotive-profits-fro-6833482176407884.html
$RLFTF by BullGodxXx -STwits: I still don't think most $BRPA people know that they only have 50% profit of U.S, Can, and Israel and do not own the rights of the drug they're riding the wave on right now. I know a lot of people are invested in both, but besides the merger and exchange listing what is to love? ROI has far greater potential here
$SNDL Strategic Investment in Edibles Adds Value to Sundial Growers The Indiva stake only enhances the bull thesis for SNDL stock as the cannabis edibles category emerges By Louis Navellier - InvestorPlace Research Staff, Editor, Growth Investor 2-22-21 https://investorplace.com/2021/02/strategic-investment-in-edibles-adds-value-to-sndl-stock/
$SNDL Strategic Investment in Edibles Adds Value to Sundial Growers The Indiva stake only enhances the bull thesis for SNDL stock as the cannabis edibles category emerges By Louis Navellier - InvestorPlace Research Staff, Editor, Growth Investor 2-22-21 https://investorplace.com/2021/02/strategic-investment-in-edibles-adds-value-to-sndl-stock/
$RLFTF Bloomberg (Covid-19) NeuroRx Announces that ZYESAMI™ (Aviptadil) has Successfully Demonstrated 10-Day Accelerated Recovery from Respiratory Failure
https://www.bloomberg.com/press-releases/2021-02-23/neurorx-announces-that-zyesami-aviptadil-has-successfully-demonstrated-10-day-accelerated-recovery-from-respiratory-failur
$RLFTF Bloomberg (Covid-19) NeuroRx Announces that ZYESAMI™ (Aviptadil) has Successfully Demonstrated 10-Day Accelerated Recovery from Respiratory Failure
https://www.bloomberg.com/press-releases/2021-02-23/neurorx-announces-that-zyesami-aviptadil-has-successfully-demonstrated-10-day-accelerated-recovery-from-respiratory-failur
$RLFTF #20 Most read boards 8.909 reads last 24 hours